Cancer detection rates of the PI-RADSv2. 1 assessment categories: systematic review and meta-analysis on lesion level and patient level

B Oerther, H Engel, F Bamberg, A Sigle… - Prostate cancer and …, 2022 - nature.com
Abstract Background The Prostate Imaging Reporting and Data System, version 2.1 (PI-
RADSv2. 1) standardizes reporting of multiparametric MRI of the prostate. Assigned …

Positive predictive value of prostate imaging reporting and data system version 2 for the detection of clinically significant prostate cancer: a systematic review and meta …

E Mazzone, A Stabile, F Pellegrino, G Basile… - European urology …, 2021 - Elsevier
Context The variability of the positive predictive value (PPV) represents a significant factor
affecting the diagnostic performance of multiparametric magnetic resonance imaging …

Update on PI-RADS version 2.1 diagnostic performance benchmarks for prostate MRI: systematic review and meta-analysis

B Oerther, A Nedelcu, H Engel, C Schmucker… - Radiology, 2024 - pubs.rsna.org
Background Prostate MRI for the detection of clinically significant prostate cancer (csPCa) is
standardized by the Prostate Imaging Reporting and Data System (PI-RADS), currently in …

Avoiding unnecessary biopsy: MRI-based risk models versus a PI-RADS and PSA density strategy for clinically significant prostate cancer

D Deniffel, GM Healy, X Dong, S Ghai… - Radiology, 2021 - pubs.rsna.org
Background In validation studies, risk models for clinically significant prostate cancer
(csPCa; Gleason score≥ 3+ 4) combining multiparametric MRI and clinical factors have …

French AFU Cancer Committee Guidelines-Update 2022-2024: prostate cancer-Diagnosis and management of localised disease

G Ploussard, G Fiard, E Barret, L Brureau… - Progrès en Urologie, 2022 - Elsevier
Objective The objective of the French Urology Association Cancer Committee is to propose
an update of the recommendations for the diagnosis and management of prostate cancer …

Diagnostic performance of prostate-specific antigen density for detecting clinically significant prostate cancer in the era of magnetic resonance imaging: a systematic …

S Wang, J Kozarek, R Russell, M Drescher… - European Urology …, 2024 - Elsevier
Context There has been a dramatic increase in the use of prostate magnetic resonance
imaging (MRI) in the diagnostic workup. With prostate volume calculated from MRI, prostate …

Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision

S Guo, J Zhang, Y Wang, J Jiao, Z Li, C Cui… - Prostate Cancer and …, 2024 - nature.com
Background Avoiding unnecessary biopsies for men with suspected prostate cancer
remains a clinical priority. The recently proposed PRIMARY score improves diagnostic …

Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer: A Systematic Review and Meta-Analysis

A Haj-Mirzaian, KS Burk, R Lacson, DI Glazer… - JAMA Network …, 2024 - jamanetwork.com
Importance Multiple strategies integrating magnetic resonance imaging (MRI) and clinical
data have been proposed to determine the need for a prostate biopsy in men with suspected …

Machine learning-based prediction of invisible intraprostatic prostate cancer lesions on 68 Ga-PSMA-11 PET/CT in patients with primary prostate cancer

Z Yi, S Hu, X Lin, Q Zou, MH Zou, Z Zhang, L Xu… - European Journal of …, 2022 - Springer
Abstract Purpose 68 Ga-PSMA PET/CT has high specificity and sensitivity for the detection
of both intraprostatic tumor focal lesions and metastasis. However, approximately 10% of …

Prostate-specific antigen density cutoff of 0.15 ng/ml/cc to propose prostate biopsies to patients with negative magnetic resonance imaging: efficient threshold or …

F Pellegrino, AL Tin, A Martini, EA Vertosick… - European urology …, 2023 - Elsevier
Background A prostate-specific antigen density (PSAd) cutoff of 0.15 ng/ml/cc is a commonly
recommended threshold to identify patients with negative prostate magnetic resonance …